Phase 1 OL, Dose Escalating, Multiple Dose Study To Determine The Safety, Tolerability, MTD, And Pharmacokinetics Of MPC-2130 Administered As Daily IV Infusions For 5 Days, Repeated Every 21 Days, In Patients With Refractory Cancer
MPC-2130 Phase 1 Clinical study was designed to evaluate its safety and pharmacokinetic
profile in patients with advanced metastatic tumors or blood cancers as well as refractory
cancers that progressed despite previous chemotherapy.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of Subjects With Dose Limiting Toxicities and Grade 3/4 Adverse Events. As a General Guideline, a Severe Adverse Event is Considered Grade 3, and a Life Threatening or Disabling Adverse Event is Considered Grade 4.
First 21 days on treatment (Cycle 1)
Richard Wenstrup, MD
Myriad Therapeutics, Inc.
United States: Food and Drug Administration
|MD Anderson Cancer Center||Houston, Texas 77030-4096|